Are These Biotech Penny Stocks On Your Watch List Right Now?
Whether you’re trading penny stocks or blue chips, the goal is the same: make money and repeat. However, with a potentially new President coming into office, there could be a few things to monitor right now. First of which could be the direction of healthcare. However, more near term events like those dealing with COVID-19 could become a bigger point of focus in the short term. If coronavirus was compared to a stock chart, we see lows in October followed by a bounce into November. This weekend saw another round of record cases with more than 1,000 deaths per day.
While both administrations (current and potential) will need to deal with this regardless, the science behind studying COVID has also brought rise to growing interest in a few other niches of biotech. Things like pain management, inflammation, and even immunotherapies have begun receiving attention from investors. Meanwhile, the latest deal from Merck (MRK Stock Report) has the company acquiring privately-held VelosBio for $2.75 billion, adding to the drug company’s portfolio of cancer drugs. With upcoming conferences, this could be a pivotal time to have biotech penny stocks on your watch list right now.
Read More
- Top Penny Stocks To Watch Right Now; 4 Vice Stocks Making New Highs
- Penny Stocks Brokerage Growth Statistics For 2020
- Are These Top Penny Stocks To Buy If Biden’s Confirmed As President?
Heading into the second half of November, we’re not just going to see earnings results, but also presentations. These presentations will likely become a much more specific focus for traders. Some are geared toward a general overview of a company’s treatment platform. Other biotechs will actually deliver phase trial results.
Biotech Penny Stocks To Watch
- GT Biopharma Inc. (GTBP Stock Report)
- Advaxis Inc. (ADXS Stock Report)
- Oncternal Therapeutics Inc. (ONCT Stock Report)
- Leap Therapeutics Inc. (LPTX Stock Report)
- IMV Inc. (IMV Stock Report)
When you’re talking about small cap stocks in the biotech sector, any “small” development can be meaningful. This goes for both positive and negative results. The long and short of it is that the path to a commercialized drug is usually long. What makes it exciting for traders? All of the interim readouts, numerous Phase trials, and the ultimate goal of commercialization or acquisition. Needless to say, heading into the new week, there’s plenty of biotech penny stocks to watch right now.
Biotech Penny Stocks To Watch #1: GT Biopharma Inc.
Much of the attention on GT Biopharma Inc. has come between the end of September and the end of October. However, bigger attention on novel cancer treatments from the like of Gilead and Merck could have a spotlight shining on small cap immunotherapy stocks right now. Furthermore, the company’s upcoming presentation at the ASH Conference during early December has also been a point of focus recently.
GT’s GTB-3550 is its lead treatment for acute myeloid leukemia and interim results will be presented in a few weeks. In the interim, the company has also given updated dose level data as well. At the end of September, GT Bio revealed that a patient in its ongoing Phase I/II GTB-3550 trial dosed with Dose Level 3 had responded favorably to treatment. Specifically, GTB-3550 at a 25mcg/kg/day dose showed a decrease in AML blast levels from 18% to 12% in the bone marrow. Furthermore, there was an improvement in marrow cellularity and improving platelet & red blood cell numbers.
What’s more, is the company’s main treatment technology that GTB-3550 is built on is gaining exposure. GT’s TriKE platform has been designed to address myriad cancer indications. The goal is to make it a true-off-the-shelf option for cancer treatment. This is in contrast to the expensive, specialized, and targeted treatments of the current “CAR-T” model some major biotechs are implementing. TriKE™ has been evaluated in ovarian, breast, prostate, pancreatic ductal adenocarcinoma, and lung cancer models.
Biotech Penny Stocks To Watch #2: Advaxis Inc.
Advaxis Inc. is another one of the biotech penny stocks to watch right now. While it hasn’t been the top performing biotech over the last 10 months, traders remain focused on it for its potential milestones.
This week could be one to have Advaxis on the watch list. The company is set to present an ePoster at the 35th Annual Meeting of the Society for Immunology of Cancer. Advaxis presents on Thursday afternoon. The important part of this presentation has everything to do with what it could mean for Advaxis. The title is, “Phase 1/2 Study of an Off-the-Shelf, Multi-Neoantigen Vector (ADXS-503) Alone and in Combination with Pembrolizumab in Subjects with Metastatic Non-Small Cell Lung Cancer.”
ADXS-503 is part of the company’s ADXS-HOT cancer-type specific immunotherapy program. It’s designed to leverage Advaxis’ Lm technology platform to target hotspot mutations that commonly occur in specific cancer types. In May of this year, the company observed partial response and one response of stable disease with 25% reduction in a target lesion with ADXS-503.
[Read More] Are These 5G Penny Stocks to Buy In November Or Should You Avoid Them?
What’s more is that responses achieved after immediate prior progression on KEYTRUDA® with previous best responses of stable disease suggest ADXS-503 may re-sensitize or enhance response to KEYTRUDA®. We’ll have to see what the company’s findings are this coming week. It’s important to weigh risk/reward here. Obviously, favorable results could suggest a bullish case, while negative findings could support a more bearish approach to ADXS.
Biotech Penny Stocks To Watch #3: Oncternal Therapeutics Inc.
Another one of the biotech penny stocks to watch from last week is Oncternal Therapeutics Inc. it’s no secret that with stocks like Aptive (APVO Stock Report) taking off, small-cap biotechs are on watch. Needless to say, even before APVO stock exploded last week, ONCT was on the watch list.
Last week the company hit the watch list after reporting its quarterly results. Oncternal recorded a third-quarter EPS loss of 22 cents compared to the 32 cent loss from last year’s Q3. Furthermore, sales came in higher, year over year at $585,000 compared to 2019’s $544,000.
Furthermore, ONCT has upcoming data to keep in mind. The company presents clinical data for over 16 patients with Ewing sarcoma at the Connective Tissue Oncology Society meeting on November 11th. Obviously, this week could become a volatile one for the company in light of this. We’ve also got to consider the clinical data update planned for presentation at the American Society for Hematology in December. Regardless of the December date, Wednesday could be a pivotal date for Oncternal depending on the outcome of these data.
Biotech Penny Stocks To Watch #4: Leap Therapeutics Inc.
Leap Therapeutics is another biopharmaceutical company to keep tabs on this week. The company acquires and develops cancer therapeutics. This week is an important one for the company. Leap presents esophagogastric cancer data for its DKN-01 monoclonal antibody at the Society of Immunotherapy of Cancer’s on November 9th. DKN-01 targets Dickkopf-related protein 1, or DKK1. It binds to and blocks the activity of the DKK1 protein.
Considering the presentation is set for pre-market on Monday, this may or may not be one of the top biotech penny stocks to watch at the top of the post-election week. Earlier this year, the FDA granted Leap orphan drug designation for DKN-01 for the treatment of gastric and gastroesophageal junction cancer.
[Read More] 3 Penny Stocks to Watch With Unique Market Opportunities
Given the timing of this, you’ve got to weigh risk/reward early this week. Making a long-story short, Monday morning could be a pivotal moment for Leap Therapeutics.
Biotech Penny Stocks To Watch #5: IMV Inc.
IMV Inc. is on this list of biotech penny stocks to watch this week as well. While the potential upcoming catalyst isn’t slated until later this week, we could be seeing some momentum already building.
Updated clinical data from phase 2 SPiReL study will be presented at the American Society of Hematology Meeting in December. It evaluates IMV’s T cell therapy in combination with Merck’s Keytruda® in patients with relapsed / refractory Diffuse Large B Cell Lymphoma (r/r DLBCL).
However, biomarkers associated with clinical response will be discussed in a separate poster presentation at the Society for Immunotherapy of Cancer Meeting. That meeting’s results are set for this coming Thursday. The company also reports 3rd quarter results this week.
Pursuant to an agreement between Midam Ventures LLC and GT Biopharma (GTBP), GT Biopharma is required to pay $200,000 per month for 4 months of services, $400,000 of which has already been paid for 2 months of services (first and last month) for a period from September 22, 2020 to January 22, 2021. We may buy or sell additional shares of GT Biopharma (GTBP) in the open market at any time, including before, during or after the Website and Information, to provide public dissemination of favorable Information about GT Biopharma (GTBP).
